Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 43
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
J Int Assoc Provid AIDS Care ; 18: 2325958219832285, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30907256

RESUMEN

In Taiwan, men who have sex with men (MSM) are at disproportionate risk of HIV infection. We examined awareness and acceptability of future HIV vaccines. From July to August 2014, we conducted a cross-sectional survey with MSM recruited through community-based organizations (CBOs) in 2 cities. Among 200 participants (mean age, 27.6 years), half reported multiple partners and one-third condomless anal sex (past 3 months); 12% were HIV-positive. Traditional Chinese medicine (TCM) use was reported by 42.7%. Over two-thirds (69.0%) were aware of HIV vaccine research, but less than half (43.8%) would accept an HIV vaccine if available. In multivariable analysis, higher educational attainment, >5 sex partners, and TCM use were positively associated with HIV vaccine awareness. Culturally informed HIV vaccine preparedness in Taiwan may be supported by a complementary approach to TCM and HIV prevention technologies, tailoring information for MSM with lower education and targeting those at high risk through gay-identified CBOs.


Asunto(s)
Vacunas contra el SIDA/administración & dosificación , Infecciones por VIH/prevención & control , Infecciones por VIH/psicología , Conocimientos, Actitudes y Práctica en Salud , Homosexualidad Masculina/psicología , Aceptación de la Atención de Salud , Adulto , Estudios Transversales , Homosexualidad Masculina/estadística & datos numéricos , Humanos , Masculino , Medicina Tradicional China/estadística & datos numéricos , Factores de Riesgo , Asunción de Riesgos , Conducta Sexual/estadística & datos numéricos , Parejas Sexuales , Taiwán , Adulto Joven
2.
Viruses ; 10(4)2018 04 01.
Artículo en Inglés | MEDLINE | ID: mdl-29614779

RESUMEN

An efficacious HIV-1 vaccine is regarded as the best way to halt the ongoing HIV-1 epidemic. However, despite significant efforts to develop a safe and effective vaccine, the modestly protective RV144 trial remains the only efficacy trial to provide some level of protection against HIV-1 acquisition. This review will outline the history of HIV vaccine development, novel technologies being applied to HIV vaccinology and immunogen design, as well as the studies that are ongoing to advance our understanding of vaccine-induced immune correlates of protection.


Asunto(s)
Vacunas contra el SIDA/inmunología , Infecciones por VIH/prevención & control , Infecciones por VIH/terapia , VIH-1/inmunología , Vacunas contra el SIDA/administración & dosificación , Animales , Anticuerpos Neutralizantes/sangre , Anticuerpos Neutralizantes/inmunología , Ensayos Clínicos como Asunto , Evaluación Preclínica de Medicamentos , Anticuerpos Anti-VIH/sangre , Anticuerpos Anti-VIH/inmunología , Infecciones por VIH/transmisión , VIH-1/genética , Interacciones Huésped-Patógeno/inmunología , Humanos , Inmunogenicidad Vacunal , Evaluación de Resultado en la Atención de Salud , Relación Estructura-Actividad , Vacunación , Proteínas Virales/química , Proteínas Virales/genética , Proteínas Virales/inmunología
3.
Hum Vaccin Immunother ; 13(12): 2996-3009, 2017 12 02.
Artículo en Inglés | MEDLINE | ID: mdl-28933684

RESUMEN

Our previous preclinical studies and a Phase I clinical trial DP6-001 have indicated that a polyvalent Env formulation was able to elicit broadly reactive antibody responses including low titer neutralizing antibody responses against viral isolates of subtypes A, B, C and AE. In the current report, a panel of 62 gp120 immunogens were screened in a rabbit model to identify gp120 immunogens that can elicit improved binding and neutralizing antibody responses and some of them can be included in the next polyvalent formulation. Only about 19% of gp120 immunogens in this panel were able to elicit neutralizing antibodies against greater than 50% of the viruses included in a high throughput PhenoSense neutralization assay when these immuongens were tested as a DNA prime followed by a fixed 5-valent gp120 protein vaccine boost. The new polyvalent formulation, using five gp120 immunogens selected from this subgroup, elicited improved quality of antibody responses in rabbits than the previous DP6-001 formulation. More significantly, this new polyvalent formulation elicited higher antibody responses against a panel of gp70V1/V2 antigens expressing V1/V2 sequences from diverse subtypes. Bioinformatics analysis supports the design of a 4-valent or 5-valent formulation using gp120 immunogens from this screening study to achieve a broad coverage against 16 HIV-1 subtypes.


Asunto(s)
Vacunas contra el SIDA/inmunología , Anticuerpos Neutralizantes/sangre , Anticuerpos Anti-VIH/sangre , Proteína gp120 de Envoltorio del VIH/inmunología , Vacunas de ADN/inmunología , Vacunas contra el SIDA/administración & dosificación , Vacunas contra el SIDA/genética , Animales , Evaluación Preclínica de Medicamentos , Proteína gp120 de Envoltorio del VIH/genética , Esquemas de Inmunización , Pruebas de Neutralización , Conejos , Vacunas de ADN/administración & dosificación , Vacunas de ADN/genética , Vacunas de Subunidad/administración & dosificación , Vacunas de Subunidad/genética , Vacunas de Subunidad/inmunología
4.
Hum Vaccin Immunother ; 13(8): 1798-1810, 2017 08 03.
Artículo en Inglés | MEDLINE | ID: mdl-28426273

RESUMEN

One of the critical issues that should be addressed in the development of a BCG-based HIV vaccine is genetic plasmid stability. Therefore, to address this issue we have considered using integrative vectors and the auxotrophic mutant of BCG complemented with a plasmid carrying a wild-type complementing gene. In this study, we have constructed an integrative E. coli-mycobacterial shuttle plasmid, p2auxo.HIVAint, expressing the HIV-1 clade A immunogen HIVA. This shuttle vector uses an antibiotic resistance-free mechanism for plasmid selection and maintenance. It was first transformed into a glycine auxotrophic E. coli strain and subsequently transformed into a lysine auxotrophic Mycobacterium bovis BCG strain to generate the vaccine BCG.HIVA2auxo.int. Presence of the HIVA gene sequence and protein expression was confirmed. We demonstrated that the in vitro stability of the integrative plasmid p2auxo.HIVAint was increased 4-fold, as compared with the BCG strain harboring the episomal plasmid, and was genetically and phenotypically characterized. The BCG.HIVA2auxo.int vaccine in combination with modified vaccinia virus Ankara (MVA).HIVA was found to be safe and induced HIV-1 and Mycobacterium tuberculosis-specific interferon-γ-producing T-cell responses in adult BALB/c mice. We have engineered a more stable and immunogenic BCG-vectored vaccine using the prototype immunogen HIVA. Thus, the use of integrative expression vectors and the antibiotic-free plasmid selection system based on "double" auxotrophic complementation are likely to improve the mycobacterial vaccine stability in vivo and immunogenicity to develop not only recombinant BCG-based vaccines expressing second generation of HIV-1 immunogens but also other major pediatric pathogens to prime protective responses shortly following birth.


Asunto(s)
Vacunas contra el SIDA/inmunología , Vacuna BCG/genética , Vacuna BCG/inmunología , Infecciones por VIH/inmunología , VIH-1/inmunología , Mycobacterium bovis/inmunología , Tuberculosis/inmunología , Vacunas contra el SIDA/administración & dosificación , Vacunas contra el SIDA/efectos adversos , Vacunas contra el SIDA/genética , Animales , Linfocitos T CD8-positivos/inmunología , Evaluación Preclínica de Medicamentos , Escherichia coli/genética , Prueba de Complementación Genética , Vectores Genéticos , Infecciones por VIH/prevención & control , VIH-1/genética , Humanos , Inmunización Secundaria , Interferón gamma/biosíntesis , Ratones , Ratones Endogámicos BALB C , Mycobacterium bovis/genética , Plásmidos/química , Plásmidos/genética , Tuberculosis/prevención & control , Vacunas Combinadas/inmunología
5.
J Control Release ; 249: 74-83, 2017 03 10.
Artículo en Inglés | MEDLINE | ID: mdl-28115243

RESUMEN

The generation of effective levels of antigen-specific immunity at the mucosal sites of pathogen entry is a key goal for vaccinologists. We explored topical vaginal application as an approach to initiate local antigen-specific immunity, enhance previously existing systemic immunity or re-target responses to the mucosae. To deliver a protein vaccine formulation to the vaginal mucosal surface, we used a novel vaginal ring device comprising a silicone elastomer body into which three freeze-dried, rod-shaped, hydroxypropylmethylcellulose inserts were incorporated. Each rod contained recombinant HIV-1 CN54gp140 protein (167µg)±R848 (167µg) adjuvant. The inserts were loaded into cavities within each ring such that only the ends of the inserts were initially exposed. Sheep received a prime-boost vaccination regime comprising intramuscular injection of 100µg CN54gp140+200µg R848 followed by three successive ring applications of one week duration and separated by one month intervals. Other sheep received only the ring devices without intramuscular priming. Serum and vaginal mucosal fluids were sampled every two weeks and analysed by CN54gp140 ELISA and antigen-specific B cells were measured by flow cytometry at necropsy. Vaccine antigen-specific serum antibody responses were detected in both the intramuscularly-primed and vaginal mucosally-primed groups. Those animals that received only vaginal vaccinations had identical IgG but superior IgA responses. Analysis revealed that all animals exhibited mucosal antigen-specific IgG and IgA with the IgA responses 30-fold greater than systemic levels. Importantly, very high numbers of antigen-specific B cells were detected in local genital draining lymph nodes. We have elicited local genital antigen-specific immune responses after topical application of an adjuvanted antigen formulation within a novel vaginal ring vaccine release device. This regimen and delivery method elicited high levels of antigen-specific mucosal IgA and large numbers of local antigen-reactive B cells, both likely essential for effective mucosal protection.


Asunto(s)
Vacunas contra el SIDA/administración & dosificación , Adyuvantes Inmunológicos/administración & dosificación , Infecciones por VIH/prevención & control , VIH-1/inmunología , Inmunidad Mucosa , Inmunización/instrumentación , Productos del Gen env del Virus de la Inmunodeficiencia Humana/administración & dosificación , Vacunas contra el SIDA/inmunología , Adyuvantes Inmunológicos/farmacología , Administración Intravaginal , Animales , Formación de Anticuerpos , Dispositivos Anticonceptivos Femeninos , Femenino , Infecciones por VIH/inmunología , Humanos , Imidazoles/administración & dosificación , Imidazoles/inmunología , Inmunidad Humoral , Inmunoglobulina A/inmunología , Inmunoglobulina G/inmunología , Ovinos , Productos del Gen env del Virus de la Inmunodeficiencia Humana/inmunología
6.
AIDS ; 31(3): 321-332, 2017 01 28.
Artículo en Inglés | MEDLINE | ID: mdl-27677160

RESUMEN

BACKGROUND: The development of a prophylactic vaccine against HIV-1 has so far not been successful. Therefore, attention has shifted more and more toward the development of novel therapeutic vaccines. Here, we evaluated a new mRNA-based therapeutic vaccine against HIV-1-encoding activation signals (TriMix: CD40L + CD70 + caTLR4) combined with rationally selected antigenic sequences [HIVACAT T-cell immunogen (HTI)] sequence: comprises 16 joined fragments from Gag, Pol, Vif, and Nef). METHODS: For this purpose, peripheral blood mononuclear cells from HIV-1-infected individuals on cART, lymph node explants from noninfected humans, and splenocytes from immunized mice were collected and several immune functions were measured. RESULTS: Electroporation of immature monocyte-derived dendritic cells from HIV-infected patients with mRNA encoding HTI + TriMix potently activated dendritic cells which resulted in upregulation of maturation markers and cytokine production and T-cell stimulation, as evidenced by enhanced proliferation and cytokine secretion (IFN-γ). Responses were HIV specific and were predominantly targeted against the sequences included in HTI. These findings were confirmed in human lymph node explants exposed to HTI + TriMix mRNA. Intranodal immunizations with HTI mRNA in a mouse model increased antigen-specific cytotoxic T-lymphocyte responses. The addition of TriMix further enhanced cytotoxic responses. CONCLUSION: Our results suggest that uptake of mRNA, encoding strong activation signals and a potent HIV antigen, confers a T-cell stimulatory capacity to dendritic cells and enhances their ability to stimulate antigen-specific immunity. These findings may pave the way for therapeutic HIV vaccine strategies based on antigen-encoding RNA to specifically target antigen-presenting cells.


Asunto(s)
Vacunas contra el SIDA/inmunología , Adyuvantes Inmunológicos/administración & dosificación , Antígenos VIH/inmunología , Infecciones por VIH/prevención & control , ARN Mensajero/genética , Vacunas contra el SIDA/administración & dosificación , Vacunas contra el SIDA/genética , Adyuvantes Inmunológicos/genética , Animales , Citocinas/metabolismo , Evaluación Preclínica de Medicamentos , Femenino , Antígenos VIH/genética , Humanos , Ratones Endogámicos C57BL , Linfocitos T/inmunología , Vacunas Sintéticas/administración & dosificación , Vacunas Sintéticas/genética , Vacunas Sintéticas/inmunología
7.
Vaccine ; 34(46): 5629-5635, 2016 11 04.
Artículo en Inglés | MEDLINE | ID: mdl-27670072

RESUMEN

In order for vaccines to induce efficacious immune responses against mucosally transmitted pathogens, such as HIV-1, activated lymphocytes must efficiently migrate to and enter targeted mucosal sites. We have previously shown that all-trans retinoic acid (ATRA) can be used as a vaccine adjuvant to enhance mucosal CD8+ T cell responses during vaccination and improve protection against mucosal viral challenge. However, the ATRA formulation is incompatible with most recombinant vaccines, and the teratogenic potential of ATRA at high doses limits its usage in many clinical settings. We hypothesized that increasing in vivo production of retinoic acid (RA) during vaccination with a DNA vector expressing retinaldehyde dehydrogenase 2 (RALDH2), the rate-limiting enzyme in RA biosynthesis, could similarly provide enhanced programming of mucosal homing to T cell responses while avoiding teratogenic effects. Administration of a RALDH2- expressing plasmid during immunization with a HIVgag DNA vaccine resulted in increased systemic and mucosal CD8+ T cell numbers with an increase in both effector and central memory T cells. Moreover, mice that received RALDH2 plasmid during DNA vaccination were more resistant to intravaginal challenge with a recombinant vaccinia virus expressing the same HIVgag antigen (VACVgag). Thus, RALDH2 can be used as an alternative adjuvant to ATRA during DNA vaccination leading to an increase in both systemic and mucosal T cell immunity and better protection from viral infection at mucosal sites.


Asunto(s)
Vacunas contra el SIDA/inmunología , Adyuvantes Inmunológicos , Inmunidad Mucosa , Retinal-Deshidrogenasa/inmunología , Vacunas de ADN/inmunología , Vacunas contra el SIDA/administración & dosificación , Vacunas contra el SIDA/genética , Familia de Aldehído Deshidrogenasa 1 , Animales , Linfocitos T CD8-positivos/inmunología , Femenino , Proteínas del Virus de la Inmunodeficiencia Humana/administración & dosificación , Proteínas del Virus de la Inmunodeficiencia Humana/genética , Proteínas del Virus de la Inmunodeficiencia Humana/inmunología , Inmunización/métodos , Memoria Inmunológica , Ratones , Plásmidos , Retinal-Deshidrogenasa/administración & dosificación , Retinal-Deshidrogenasa/genética , Tretinoina/inmunología , Tretinoina/metabolismo , Vacunas de ADN/administración & dosificación , Vaccinia/inmunología , Vaccinia/prevención & control , Virus Vaccinia/genética
8.
Hum Vaccin Immunother ; 12(12): 3020-3028, 2016 12.
Artículo en Inglés | MEDLINE | ID: mdl-27560197

RESUMEN

Granulocyte macrophage-colony stimulating factor (GM-CSF) is a potent immunomodulatory cytokine that is known to facilitate vaccine efficacy by promoting the development and prolongation of both humoral and cellular immunity. In the past years we have generated a novel codon-optimized GM-CSF gene as an adjuvant. The codon-optimized GM-CSF gene significantly increased protein expression levels in all cells tested and helped in generating a strong immune responses against HIV-1 Gag and HPV-associated cancer. Here, we review the literature dealing with the adjuvant activity of GM-CSF both in animal models and clinical trials. We anticipate that the codon-optimized GM-CSF gene offers a practical molecular strategy for potentiating immune responses to tumor cell-based vaccinations as well as other immunotherapeutic strategies.


Asunto(s)
Vacunas contra el SIDA/inmunología , Adyuvantes Inmunológicos/administración & dosificación , Vacunas contra el Cáncer/inmunología , Factor Estimulante de Colonias de Granulocitos y Macrófagos/administración & dosificación , Vacunas contra el SIDA/administración & dosificación , Adyuvantes Inmunológicos/genética , Animales , Vacunas contra el Cáncer/administración & dosificación , Ensayos Clínicos como Asunto , Evaluación Preclínica de Medicamentos , Factor Estimulante de Colonias de Granulocitos y Macrófagos/genética , Humanos , Modelos Animales
9.
PLoS One ; 11(6): e0157353, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27300145

RESUMEN

An important feature of a potential vaccine against HIV is the production of broadly neutralising antibodies (BrNAbs) capable of potentially blocking infectivity of a diverse array of HIV strains. BrNAbs naturally arise in some HIV infected individuals after several years of infection and their serum IgG can neutralise various HIV strains across different subtypes. We previously showed that vaccination of cows with HIV gp140 AD8 trimers resulted in a high titre of serum IgG against HIV envelope (Env) that had strong BrNAb activity. These polyclonal BrNAbs concentrated into the colostrum during the late stage of pregnancy and can be harvested in vast quantities immediately after calving. In this study, we investigated the effect of prolonged HIV gp140 vaccination on bovine colostrum IgG HIV Env-binding and BrNAb activity over subsequent pregnancies. Repeated immunisation led to a maintained high titre of HIV Env specific IgG in the colostrum batches, but this did not increase through repeated cycles. Colostrum IgG from all batches also strongly competed with sCD4 binding to gp140 Env trimer and with human-derived monoclonal VRC01 and b12 BrNAbs that bind the CD4 binding site (CD4bs). Furthermore, competition neutralisation assays using RSC3 Env gp120 protein core and a derivative CD4bs mutant, RSC3 Δ371I/P363N, showed that CD4bs neutralising antibodies contribute to the neutralising activity of all batches of purified bovine colostrum IgG. This result indicates that the high IgG titre/avidity of anti-CD4bs antibodies with BrNAb activity was achieved during the first year of vaccination and was sustained throughout the years of repeated vaccinations in the cow tested. Although IgG of subsequent colostrum batches may have a higher avidity towards the CD4bs, the overall breadth in neutralisation was not enhanced. This implies that the boosting vaccinations over 4 years elicited a polyclonal antibody response that maintained the proportion of both neutralising and non-neutralising CD4bs antibodies.


Asunto(s)
Vacunas contra el SIDA/inmunología , Anticuerpos Neutralizantes/inmunología , Anticuerpos Anti-VIH/inmunología , Infecciones por VIH/prevención & control , Productos del Gen env del Virus de la Inmunodeficiencia Humana/inmunología , Vacunas contra el SIDA/administración & dosificación , Animales , Antígenos CD4/inmunología , Bovinos , Calostro/inmunología , Calostro/virología , Femenino , Infecciones por VIH/inmunología , Células HeLa , Humanos , Embarazo , Vacunación
10.
Hum Vaccin Immunother ; 12(3): 829-36, 2016 03 03.
Artículo en Inglés | MEDLINE | ID: mdl-26479036

RESUMEN

The rapid occurrence of emerging infectious diseases demonstrates an urgent need for a new preclinical experimental model that reliably replicates human immune responses. Here, a new homozygous humanized human leukocyte antigen (HLA)-A11/DR1 transgenic mouse (HLA-A11(+/+)/DR01(+/+)/H-2-ß2m(-/-)/IAß(-/-)) was generated by crossing HLA-A11 transgenic (Tg) mice with HLA-A2(+/+)/DR01(+/+)/H-2-ß2m(-/-)/IAß(-/-) mice. The HLA-A11-restricted immune response of this mouse model was then examined. HLA-A11 Tg mice expressing a chimeric major histocompatibility complex (MHC) molecule comprising the α1, α2, and ß2m domains of human HLA-A11 and the α3 transmembrane and cytoplasmic domains of murine H-2D(b) were generated. The correct integration of HLA-A11 and HLA-DR1 into the genome of the HLA-A11/DR1 Tg mice (which lacked the expression of endogenous H-2-I/II molecules) was then confirmed. Immunizing mice with a recombinant HBV vaccine or a recombinant HIV-1 protein resulted in the generation of IFN-γ-producing cytotoxic T lymphocyte (CTL) and antigen-specific antibodies. The HLA-A11-restricted CTL response was directed at HLA immunodominant epitopes. These mice represent a versatile animal model for studying the immunogenicity of HLA CTL epitopes in the absence of a murine MHC response. The established animal model will also be useful for evaluating and optimizing T cell-based vaccines and for studying differences in antigen processing between mice and humans.


Asunto(s)
Vacunas contra el SIDA/inmunología , Evaluación Preclínica de Medicamentos/métodos , Antígeno HLA-A11/genética , Antígeno HLA-DR1/genética , Vacunas contra Hepatitis B/inmunología , Ratones Transgénicos , Vacunas contra el SIDA/administración & dosificación , Animales , Cruzamientos Genéticos , Anticuerpos Anti-VIH/sangre , Anticuerpos contra la Hepatitis B/sangre , Vacunas contra Hepatitis B/administración & dosificación , Homocigoto , Humanos , Interferón gamma/metabolismo , Modelos Animales , Linfocitos T/inmunología
11.
J Virol ; 89(15): 7478-93, 2015 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-25972551

RESUMEN

UNLABELLED: Eliciting broadly reactive functional antibodies remains a challenge in human immunodeficiency virus type 1 (HIV-1) vaccine development that is complicated by variations in envelope (Env) subtype and structure. The majority of new global HIV-1 infections are subtype C, and novel antigenic properties have been described for subtype C Env proteins. Thus, an HIV-1 subtype C Env protein (CO6980v0c22) from an infected person in the acute phase (Fiebig stage I/II) was developed as a research reagent and candidate immunogen. The gp145 envelope is a novel immunogen with a fully intact membrane-proximal external region (MPER), extended by a polylysine tail. Soluble gp145 was enriched for trimers that yielded the expected "fan blade" motifs when visualized by cryoelectron microscopy. CO6980v0c22 gp145 reacts with the 4E10, PG9, PG16, and VRC01 HIV-1 neutralizing monoclonal antibodies (MAbs), as well as the V1/V2-specific PGT121, 697, 2158, and 2297 MAbs. Different gp145 oligomers were tested for immunogenicity in rabbits, and purified dimers, trimers, and larger multimers elicited similar levels of cross-subtype binding and neutralizing antibodies to tier 1 and some tier 2 viruses. Immunized rabbit sera did not neutralize the highly resistant CO6980v0c22 pseudovirus but did inhibit the homologous infectious molecular clone in a peripheral blood mononuclear cell (PBMC) assay. This Env is currently in good manufacturing practice (GMP) production to be made available for use as a clinical research tool and further evaluation as a candidate vaccine. IMPORTANCE: At present, the product pipeline for HIV vaccines is insufficient and is limited by inadequate capacity to produce large quantities of vaccine to standards required for human clinical trials. Such products are required to evaluate critical questions of vaccine formulation, route, dosing, and schedule, as well as to establish vaccine efficacy. The gp145 Env protein presented in this study forms physical trimers, binds to many of the well-characterized broad neutralizing MAbs that target conserved Env epitopes, and induce cross-subtype neutralizing antibodies as measured in both cell line and primary cell assays. This subtype C Env gp145 protein is currently undergoing good manufacturing practice production for use as a reagent for preclinical studies and for human clinical research. This product will serve as a reagent for comparative studies and may represent a next-generation candidate HIV immunogen.


Asunto(s)
Vacunas contra el SIDA/inmunología , Infecciones por VIH/inmunología , VIH-1/inmunología , Productos del Gen env del Virus de la Inmunodeficiencia Humana/inmunología , Vacunas contra el SIDA/administración & dosificación , Vacunas contra el SIDA/genética , Animales , Evaluación Preclínica de Medicamentos , Anticuerpos Anti-VIH/inmunología , Infecciones por VIH/prevención & control , Infecciones por VIH/virología , VIH-1/genética , Humanos , Leucocitos Mononucleares/inmunología , Datos de Secuencia Molecular , Pruebas de Neutralización , Conejos , Vacunación , Productos del Gen env del Virus de la Inmunodeficiencia Humana/administración & dosificación , Productos del Gen env del Virus de la Inmunodeficiencia Humana/genética
12.
Stat Med ; 34(10): 1747-60, 2015 May 10.
Artículo en Inglés | MEDLINE | ID: mdl-25628249

RESUMEN

A critical step toward developing a successful vaccine to control the human immunodeficiency virus pandemic entails evaluation of vaccine candidates in non-human primates (NHPs). Historically, these studies have usually entailed challenges (i.e., exposures) with very high doses of a simian version of human immunodeficiency virus, resulting in infection of all NHPs in the experiment after a single challenge. More recently, researchers have begun to conduct repeated low-dose challenge (RLC) studies in NHPs that are believed to more closely mimic typical exposure in natural human transmission settings. One objective of RLC studies is to assess whether measured immune responses to vaccination can serve as surrogate endpoints for the primary endpoint of interest, namely infection. In this paper, different designs of RLC studies for assessing a binary surrogate of protection are considered.


Asunto(s)
Vacunas contra el SIDA/administración & dosificación , Infecciones por VIH/inmunología , Primates/inmunología , Síndrome de Inmunodeficiencia Adquirida del Simio/inmunología , Virus de la Inmunodeficiencia de los Simios/inmunología , Vacunas contra el SIDA/inmunología , Animales , Distribución Binomial , Simulación por Computador , Estudios Cruzados , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos/métodos , Infecciones por VIH/prevención & control , Humanos , Funciones de Verosimilitud , Primates/virología , Síndrome de Inmunodeficiencia Adquirida del Simio/prevención & control , Virus de la Inmunodeficiencia de los Simios/patogenicidad
13.
Vaccine ; 33(27): 3073-83, 2015 Jun 17.
Artículo en Inglés | MEDLINE | ID: mdl-25510387

RESUMEN

The use of a number of non-rhesus macaque species, but especially cynomolgus macaques as a model for HIV-1 vaccine development has increased in recent years. Cynomolgus macaques have been used in the United Kingdom, Europe, Canada and Australia as a model for HIV vaccine development for many years. Unlike rhesus macaques, cynomolgus macaques infected with SIV show a pattern of disease pathogenesis that more closely resembles that of human HIV-1 infection, exhibiting lower peak and set-point viral loads and slower progression to disease with more typical AIDS defining illnesses. Several advances have been made recently in the use of the cynomolgus macaque SIV challenge model that allow the demonstration of vaccine efficacy using attenuated viruses and vectors that are both viral and non-viral in origin. This review aims to probe the details of various vaccination trials carried out in cynomolgus macaques in the context of our modern understanding of the highly diverse immunogenetics of this species with a view to understanding the species-specific immune correlates of protection and the efficacy of vectors that have been used to design vaccines.


Asunto(s)
Vacunas contra el SIDA/administración & dosificación , Vacunas contra el SIDA/inmunología , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos/métodos , Macaca fascicularis , Vacunas contra el SIDAS/administración & dosificación , Vacunas contra el SIDAS/inmunología , Animales
14.
Curr Opin HIV AIDS ; 8(5): 412-20, 2013 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-23925001

RESUMEN

PURPOSE OF REVIEW: We review the broad spectrum of nonreplicating viral vectors which have been studied extensively, from preclinical studies through clinical efficacy trials, and include some of our most promising HIV vaccine candidates. RECENT FINDINGS: The success of the RV144 trial, with a canarypox virus-based regimen, contrasts with the failures of the adenovirus-5 (Ad5)-based regimens in the Step study, the Phambili study [HIV Vaccine Trials Network (HVTN) 503], and the HVTN 505 study which was recently modified to halt vaccinations because of clinical futility. SUMMARY: The safety profile, immunogenicity, and variety of available candidates make the nonreplicating viral vectors attractive in HIV vaccine development. Building from the success of the RV144 study, further studies of Orthopoxvirus-based vaccines, including vaccinia-based vaccines, are ongoing and planned for the future. Despite the failures of the Ad5-based vaccines in clinical efficacy trials, other adenovirus serotypes remain promising candidates, especially in prime-boost combination with other products, and with the potential use of mosaic inserts. Other nonreplicating viral vectors such as the rhabdoviruses, alphaviruses, and the nonhuman adenoviruses, provide additional avenues for exploration.


Asunto(s)
Vacunas contra el SIDA/genética , Vacunas contra el SIDA/inmunología , Portadores de Fármacos , Vectores Genéticos , Infecciones por VIH/prevención & control , Vacunas contra el SIDA/administración & dosificación , Vacunas contra el SIDA/efectos adversos , Adenoviridae/genética , Animales , Virus de la Viruela de los Canarios/genética , Ensayos Clínicos como Asunto , Evaluación Preclínica de Medicamentos , Humanos , Orthopoxvirus/genética , Resultado del Tratamiento
15.
Expert Opin Biol Ther ; 13(2): 197-207, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23130709

RESUMEN

INTRODUCTION: One of the challenges facing the development of an AIDS vaccine is eliciting antibody (Ab) capable of preventing the acquisition of HIV. Broadly neutralizing Ab (bnAb) that can prevent HIV infection has proven to be difficult to elicit. Here, we consider the potential for protective non-neutralizing Ab (pnnAb) to provide the much needed Ab component for an HIV vaccine. Such Ab acts by "tagging" virus or infected cells for destruction by the innate immune system. AREAS COVERED: We review interactions between the Fc region of immunoglobulin G (IgG) and Fcϒ receptors or complement that can lead to the destruction of HIV or HIV-infected cells, correlations between the presence of pnnAb and the prevention of HIV and simian immunodeficiency virus (SIV) infections, differences between classical HIV-specific bnAb and HIV-specific pnnAb, HIV envelope antigens and adjuvants which have been hypothesized to generate pnnAb, and the use of avidity as a serological correlate for pnnAb. EXPERT OPINION: We hypothesize that selection of HIV for the poor ability to elicit bnAb has also selected it for slow entry into cells and a window of opportunity for pnnAb to tag virus for destruction by innate immune responses.


Asunto(s)
Anticuerpos Neutralizantes/uso terapéutico , Infecciones por VIH/prevención & control , Vacunas contra el SIDA/administración & dosificación , Vacunas contra el SIDA/inmunología , Animales , Citotoxicidad Celular Dependiente de Anticuerpos , Evaluación Preclínica de Medicamentos , VIH/inmunología , Humanos , Macaca mulatta , Receptores Fc/inmunología
16.
J Immunol Methods ; 386(1-2): 10-21, 2012 Dec 14.
Artículo en Inglés | MEDLINE | ID: mdl-22955212

RESUMEN

Vaccination and SIV challenge of macaque species is the best animal model for evaluating candidate HIV vaccines in pre-clinical studies. As such, robust assays optimized for use in nonhuman primates are necessary for reliable ex vivo measurement of immune responses and identification of potential immune correlates of protection. We optimized and qualified an 8-color intracellular cytokine staining assay for the measurement of IFNγ, IL-2, and TNF from viable CD4 and CD8 T cells from cryopreserved rhesus macaque PBMC stimulated with peptides. After optimization, five laboratories tested assay performance using the same reagents and PBMC samples; similar results were obtained despite the use of flow cytometers with different configurations. The 8-color assay was then subjected to a pre-qualification study to quantify specificity and precision. These data were used to set positivity thresholds and to design the qualification protocol. Upon completion of the qualification study, the assay was shown to be highly reproducible with low inter-aliquot, inter-day, and inter-operator variability according to the qualification criteria with an overall variability of 20-40% for each outcome measurement. Thus, the 8-color ICS assay was formally qualified according to the ICH guidelines Q2 (R1) for specificity and precision indicating that it is considered a standardized/robust assay acceptable for use in pre-clinical trial immunogenicity testing.


Asunto(s)
Vacunas contra el SIDA/administración & dosificación , Citocinas/análisis , Síndrome de Inmunodeficiencia Adquirida del Simio/inmunología , Virus de la Inmunodeficiencia de los Simios/inmunología , Coloración y Etiquetado/métodos , Linfocitos T/inmunología , Animales , Separación Celular , Color , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Citometría de Flujo/métodos , Guías como Asunto , Humanos , Espacio Intracelular , Macaca mulatta , Variaciones Dependientes del Observador , Reproducibilidad de los Resultados , Sensibilidad y Especificidad
17.
Viral Immunol ; 25(2): 131-40, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22486304

RESUMEN

Interleukin-21 (IL-21) is a T-cell-derived cytokine that modulates T-cell, B-cell, and natural killer cell responses. It is not known if it could be used as an adjuvant for HIV DNA vaccination. In our study, we investigated if a DNA construct expressing IL-21 (designated as pVAX-IL-21) as a molecule adjuvant could enhance antigen-specific immune responses to an HIV DNA vaccine (pGX-EnvC). We found that a higher level of antigen-specific cytotoxic responses was induced in BALB/C mice immunized with pGX-EnvC with the pVAX-IL-21 via electroporation. The increased response was associated with higher expression of IFN-γ in CD8⁺ T cells. In contrast, the administration of pVAX-IL-21 inhibited the antibody responses to HIV induced by the pGX-EnvC. The plasma cell inhibitory transcription factors B-cell lymphoma 6 protein (Bcl-6) and Pax-5 were increased in B cells from mice that had been immunized by HIV DNA vaccine plus pVAX-IL-21, suggesting that the expressed IL-21 may inhibit the differentiation from B cells to plasma cells. These results indicate that IL-21 could enhance CD8⁺ T-cell immunity, but inhibit humoral responses during HIV DNA vaccination.


Asunto(s)
Vacunas contra el SIDA/inmunología , Proteínas de Unión al ADN/antagonistas & inhibidores , Anticuerpos Anti-VIH/sangre , Factores Inmunológicos/administración & dosificación , Interleucinas/administración & dosificación , Factor de Transcripción PAX5/antagonistas & inhibidores , Vacunas de ADN/inmunología , Vacunas contra el SIDA/administración & dosificación , Animales , Linfocitos T CD8-positivos/inmunología , Femenino , Ratones , Ratones Endogámicos BALB C , Proteínas Proto-Oncogénicas c-bcl-6 , Vacunas de ADN/administración & dosificación
18.
Glob Public Health ; 7(1): 87-100, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-21390966

RESUMEN

This study explored HIV vaccine acceptability and strategies for culturally appropriate dissemination among sexually diverse Aboriginal peoples in Canada, among those at highest HIV risk. We conducted four focus groups (n=23) with Aboriginal male (1) and female (1) service users, peer educators (1) and service providers (1) in Ontario, Canada. Transcripts were analysed with narrative thematic techniques from grounded theory, using NVivo. Participants' mean age was 37 years; about half (52%) were female, half (48%) Two-spirit or lesbian, gay or bisexual (LGB)-identified, 48% had a high-school education or less and 57% were unemployed. Vaccine uptake was motivated by community survival; however, negative HIV vaccine perceptions, historically based mistrust of government and healthcare institutions, perceived conflict between western and traditional medicine, sexual prejudice and AIDS stigma within and outside of Aboriginal communities, and vaccine cost may present formidable obstacles to HIV vaccine acceptability. Culturally appropriate processes of engagement emerged on individual levels (i.e., respect for self-determination, explanations in Native languages, use of modelling and traditional healing concepts) and community levels (i.e., leadership by Aboriginal HIV advocates and political representatives, identification of gatekeepers, and procuring Elders' endorsements). Building on cultural strengths and acknowledging the history and context of mistrust and social exclusion are fundamental to effective HIV vaccine dissemination.


Asunto(s)
Vacunas contra el SIDA/administración & dosificación , Competencia Cultural , Infecciones por VIH/etnología , Educación en Salud/normas , Servicios de Salud del Indígena/normas , Aceptación de la Atención de Salud/etnología , Conducta Sexual/etnología , Vacunas contra el SIDA/normas , Participación de la Comunidad , Femenino , Grupos Focales , Infecciones por VIH/prevención & control , Infecciones por VIH/transmisión , Educación en Salud/métodos , Servicios de Salud del Indígena/estadística & datos numéricos , Humanos , Indígenas Norteamericanos/psicología , Indígenas Norteamericanos/estadística & datos numéricos , Inuk/psicología , Inuk/estadística & datos numéricos , Masculino , Ontario/epidemiología , Aceptación de la Atención de Salud/psicología , Grupo Paritario , Prevalencia , Conducta Sexual/estadística & datos numéricos
19.
J Virol ; 86(1): 108-13, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22013040

RESUMEN

Human immunodeficiency virus (HIV) infection is associated with immune activation, CD4⁺-T-cell loss, and a progressive decline of immune functions. Antiretroviral therapy (ART) only partially reverses HIV-associated immune dysfunction, suggesting that approaches that target immune activation and improve virus-specific immune responses may be needed. We performed a preclinical study in rhesus macaques infected with the pathogenic simian immunodeficiency virus SIV(mac251) and treated with ART. We tested whether vaccination administered together with cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) blockade and treatment with the indoleamine 2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan (D-1mT), decreased immune activation and improved vaccine efficacy. The treatment did not augment vaccine immunogenicity; rather, it dramatically increased ART-related toxicity, causing all treated animals to succumb to acute pancreatitis and hyperglycemic coma. The onset of fulminant diabetes was associated with severe lymphocyte infiltration of the pancreas and complete loss of the islets of Langerhans. Thus, caution should be used when considering approaches aimed at targeting immune activation during ART.


Asunto(s)
Fármacos Anti-VIH/efectos adversos , Didanosina/efectos adversos , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/inmunología , Pancreatitis/etiología , Virus de la Inmunodeficiencia de los Simios/fisiología , Estavudina/efectos adversos , Vacunas contra el SIDA/administración & dosificación , Vacunas contra el SIDA/inmunología , Animales , Fármacos Anti-VIH/uso terapéutico , Antígeno CTLA-4/antagonistas & inhibidores , Didanosina/uso terapéutico , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Quimioterapia Combinada/efectos adversos , Infecciones por VIH/complicaciones , Infecciones por VIH/virología , VIH-1/efectos de los fármacos , VIH-1/inmunología , VIH-1/fisiología , Humanos , Indolamina-Pirrol 2,3,-Dioxigenasa/antagonistas & inhibidores , Macaca mulatta , Pancreatitis/inmunología , Pancreatitis/mortalidad , Virus de la Inmunodeficiencia de los Simios/efectos de los fármacos , Virus de la Inmunodeficiencia de los Simios/inmunología , Estavudina/uso terapéutico , Triptófano/efectos adversos , Triptófano/análogos & derivados , Triptófano/uso terapéutico
20.
Vaccine ; 29(13): 2429-36, 2011 Mar 16.
Artículo en Inglés | MEDLINE | ID: mdl-21272602

RESUMEN

Non-replicating protein- or DNA-based antigens generally require immune-enhancing adjuvants and delivery systems. It has been particularly difficult to raise antibodies against gp120 of HIV-1, which constitutes an important approach in HIV vaccine design. While almost all effort in adjuvant research has focused on mimicking the pathogens and the danger signals they engender in the host, relatively little effort has been spent on nutritive approaches. In this study, a new nutritive immune-enhancing delivery system (NIDS) composed of vitamin A, a polyphenol-flavonoid, catechin hydrate, and mustard oil was tested for its adjuvant effect in immune responses against the gp120 protein of HIV-1(CN54). Following a combination of two mucosal and two systemic vaccinations of mice, we found significant enhancement of both local and systemic antibodies as well as cytokine responses. These data have important implications for vaccine and adjuvant design against HIV-1 and other pathogens.


Asunto(s)
Vacunas contra el SIDA/administración & dosificación , Vacunas contra el SIDA/inmunología , Adyuvantes Inmunológicos/farmacología , Catequina/farmacología , Emulsiones/farmacología , Aceites de Plantas/farmacología , Tretinoina/farmacología , Animales , Citocinas/inmunología , Citocinas/metabolismo , Femenino , Anticuerpos Anti-VIH/sangre , Anticuerpos Anti-VIH/inmunología , Proteína gp120 de Envoltorio del VIH/administración & dosificación , Proteína gp120 de Envoltorio del VIH/inmunología , Inmunización Secundaria/métodos , Ratones , Ratones Endogámicos BALB C , Planta de la Mostaza , Vacunación/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA